Provided by Tiger Trade Technology Pte. Ltd.

ProMIS Neurosciences Inc

14.74
-0.3900-2.58%
Post-market: 14.740.00000.00%19:39 EDT
Volume:31.68K
Turnover:468.78K
Market Cap:132.18M
PE:-0.65
High:15.34
Open:14.79
Low:14.26
Close:15.13
52wk High:39.75
52wk Low:6.27
Shares:8.97M
Float Shares:1.02M
Volume Ratio:1.69
T/O Rate:3.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-22.6100
EPS(LYR):-22.6100
ROE:-521.61%
ROA:-178.72%
PB:-105.03
PE(LYR):-0.65

Loading ...

ProMIS Neurosciences Inc expected to post a loss of $1.91 a share - Earnings Preview

Reuters
·
Mar 27

ProMIS Neurosciences Files $200 Million Mixed Shelf

MT Newswires Live
·
Mar 26

ProMIS Neurosciences files $200M mixed securities shelf

TIPRANKS
·
Mar 26

ProMIS Neurosciences Inc - May Offer up to $50 Mln Common Shares Under Sales Agreement - SEC Filing

THOMSON REUTERS
·
Mar 26

ProMIS Neurosciences Q4 EPS $(21.83) Misses $(0.21) Estimate

Benzinga
·
Mar 25

ProMIS Neurosciences FY2025 net loss rises to $40 million; R&D expenses more than tripled to $33 million

Reuters
·
Mar 25

ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights

GlobeNewswire
·
Mar 25

ProMIS Neurosciences to present ALS and Parkinson’s data at AD/PD 2026 conference

Reuters
·
Mar 18

ProMIS Neurosciences Director Eugene Williams Acquires Common Shares

Reuters
·
Mar 06

ProMIS Neurosciences Director Eugene Williams Reports Acquisition of Common Shares

Reuters
·
Mar 05

ABG V-SIV IX Ltd Files Initial Beneficial Ownership Statement for ProMIS Neurosciences Inc

Reuters
·
Feb 26

ProMIS Chief Development Officer Johanne Kaplan Acquires Common Shares

Reuters
·
Feb 23

ProMIS Neurosciences Is Maintained at Buy by Guggenheim

Dow Jones
·
Feb 06

ABG Management Ltd. Reports Acquisition of ProMIS Neurosciences Common Shares

Reuters
·
Feb 06

ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

GlobeNewswire
·
Feb 05

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:09 AM

Reuters
·
Jan 30

Promis Neurosciences Inc trading halted, volatility trading pause

TIPRANKS
·
Jan 30

ProMIS Neurosciences : Proceeds Expected to Enable Completion of ProMIS' Landmark Phase 1B Ad Study and Support Execution of Key Clinical Milestones

THOMSON REUTERS
·
Jan 30

ProMIS Neurosciences Inc: Extends Cash Runway Into 2028

THOMSON REUTERS
·
Jan 30

ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing

GlobeNewswire
·
Jan 30